Castle Biosciences, Inc. Common Stock
CSTLCastle Biosciences, Inc. is a dermatologic oncology company focused on developing assays that assist in diagnosing, prognosing, and managing skin cancer. The company specializes in providing molecular diagnostic tests aimed at improving clinical decision-making and patient care for various skin cancers, including melanoma and dermatologic conditions. Founded in 2010, Castle Biosciences is committed to advancing personalized medicine through innovative diagnostic technologies.
Company News
A systematic review and meta-analysis demonstrates that TissueCypher® Barrett's Esophagus test can more accurately identify patients at risk of developing esophageal cancer compared to traditional pathology methods.
Castle Biosciences has been named a Houston Top Workplace for the fifth consecutive year, earning recognition for employee culture, including awards in Employee Appreciation, Employee Well-Being, and Professional Development.
Castle Biosciences announced its Q3 2025 financial results and launched AdvanceAD-Tx, a genetic expression test to help guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis aged 12 and older.
Castle Biosciences presented research demonstrating its TissueCypher test can provide advanced risk insights for Barrett's esophagus patients, potentially helping clinicians identify and intervene earlier for patients at higher risk of esophageal cancer progression.
Castle Biosciences will release its Q3 2025 financial results on November 3, 2025, after market close, with a conference call and webcast to discuss the results at 4:30 p.m. Eastern time.
